BioMarin Pharma (BMRN) Tops Q2 EPS by 61c ; Offers Guidance
Tweet
Share
E-mail
Get Alerts BMRN Hot Sheet
Price: $66.97 --0%
Revenue Growth %: +32.7%
Financial Fact:
Total revenues: 279.9M
Today's EPS Names:
FIZZ, BNED, AOUT, More
Revenue Growth %: +32.7%
Financial Fact:
Total revenues: 279.9M
Today's EPS Names:
FIZZ, BNED, AOUT, More
Join SI Premium – FREE
BioMarin Pharma (NASDAQ: BMRN) reported Q2 EPS of $0.96, $0.61 better than the analyst estimate of $0.35. Revenue for the quarter came in at $712 million versus the consensus estimate of $662.05 million.
GUIDANCE:
BioMarin Pharma sees FY2024 EPS of $3.10-$3.25, versus the consensus of $2.87. BioMarin Pharma sees FY2024 revenue of $2.75-2.82 billion, versus the consensus of $2.74 billion.
For earnings history and earnings-related data on BioMarin Pharma (BMRN) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Momo (MOMO) Tops Q2 EPS by 8c; offers guidance
- Netskope, Inc. (NTSK) Tops Q2 EPS by 4c, Offers Guidance
- BioMarin Pharmaceutical Inc. (BMRN) PT Raised to $109 at Raymond James
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
